Viewing Study NCT01625234

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:20 AM
Ignite Modification Date: 2026-02-24 @ 6:09 PM
Study NCT ID: NCT01625234
Status: COMPLETED
Last Update Posted: 2021-10-06
First Post: 2012-06-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Sponsor: Xcovery Holdings, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumors View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None Cancer View
None Tumors View
None ALK View
None Advanced Malignancies View
None Carcinoma, Non-Small-Cell Lung View
None Inflammatory Myofibroblastic Tumors View